Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690975 · ClinicalTrials.gov registry record · Phase 1
Benzonatate Dose Tolerance Study
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01690975 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 9 participants.
The verdict
NCT01690975, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single-center, randomized, third party blind, placebo controlled, dose escalation study of benzonatate following single dose administration. The primary oobjective is to assess the safety and tolerability of increasing oral doses of benzonatate following single dose administration in healthy male and female subjects.
Interventions
- DRUG Placebo
- DRUG Benzonatate - 400 mg
- DRUG Benzonatate - 600 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01690975
The ClinicalTrials.gov registry entry for NCT01690975 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01690975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01690975 about?
NCT01690975 is a clinical study titled "Benzonatate Dose Tolerance Study". This is a single-center, randomized, third party blind, placebo controlled, dose escalation study of benzonatate following single dose administration. The primary oobjective is to assess the safety and tolerability of increasing oral doses of benzonatate following single dose administration in healt...
What is the current status of trial NCT01690975?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01690975?
The interventions under investigation include: Placebo (DRUG), Benzonatate - 400 mg (DRUG), Benzonatate - 600 mg (DRUG).
Who is sponsoring clinical trial NCT01690975?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.